Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,335,408
  • Shares Outstanding, K 2,504,138
  • Annual Sales, $ 42,147 M
  • Annual Income, $ 3,256 M
  • 60-Month Beta 0.62
  • Price/Sales 3.18
  • Price/Cash Flow 11.88
  • Price/Book 1.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.81
  • Number of Estimates 1
  • High Estimate 0.81
  • Low Estimate 0.81
  • Prior Year 0.81
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.72 +6.56%
on 01/27/20
51.72 -1.68%
on 02/06/20
+0.64 (+1.27%)
since 01/21/20
3-Month
45.17 +12.57%
on 12/03/19
51.84 -1.91%
on 01/10/20
+3.68 (+7.80%)
since 11/21/19
52-Week
40.00 +27.12%
on 08/05/19
51.84 -1.91%
on 01/10/20
+9.52 (+23.03%)
since 02/21/19

Most Recent Stories

More News
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

TEVA : 13.19 (-0.90%)
SNY : 50.85 (+0.20%)
PRGO : 59.86 (+0.42%)
EBS : 65.94 (+2.11%)
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

JNJ : 149.93 (+1.05%)
SNY : 50.85 (+0.20%)
AZN : 50.17 (+2.51%)
RHHBY : 44.0300 (+0.39%)
PFE : 35.72 (-0.36%)
MRK : 82.34 (-0.18%)
NVS : 96.76 (+0.49%)
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

SNY : 50.85 (+0.20%)
AMAG : 9.50 (+0.85%)
AMGN : 222.79 (+0.29%)
AMRN : 17.93 (+0.34%)
Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine

Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.

JNJ : 149.93 (+1.05%)
REGN : 403.15 (+1.00%)
SNY : 50.85 (+0.20%)
GSK : 43.08 (+0.75%)
Regeneron Reports Positive Eylea Data From Late-Stage Study

Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.

REGN : 403.15 (+1.00%)
SNY : 50.85 (+0.20%)
NVS : 96.76 (+0.49%)
BAYRY : 20.0699 (-0.79%)
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

SNY : 50.85 (+0.20%)
NVO : 63.85 (+0.54%)
ABBV : 94.96 (+0.77%)
MRK : 82.34 (-0.18%)
BMY : 65.63 (+0.71%)
GSK : 43.08 (+0.75%)
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat

Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.

NVS : 96.76 (+0.49%)
SNY : 50.85 (+0.20%)
ALNY : 131.03 (-1.57%)
REGN : 403.15 (+1.00%)
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong

Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales

SNY : 50.85 (+0.20%)
LLY : 142.04 (+0.03%)
AMGN : 222.79 (+0.29%)
REGN : 403.15 (+1.00%)
Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.

NVS : 96.76 (+0.49%)
SNY : 50.85 (+0.20%)
BAYRY : 20.0699 (-0.79%)
REGN : 403.15 (+1.00%)
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

PFE : 35.72 (-0.36%)
NVO : 63.85 (+0.54%)
RHHBY : 44.0300 (+0.39%)
SNY : 50.85 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 51.38
1st Resistance Point 51.12
Last Price 50.85
1st Support Level 50.35
2nd Support Level 49.84

See More

52-Week High 51.84
Last Price 50.85
Fibonacci 61.8% 47.32
Fibonacci 50% 45.92
Fibonacci 38.2% 44.52
52-Week Low 40.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar